The Priority Review

Tag

SHR-3167

1 story

  1. Clinical trials

    Jiangsu HengRui Medicine registers Phase 3 trial of SHR-3167 vs insulin degludec in type 2 diabetes

    The study, led by Jiangsu HengRui Medicine Co., Ltd., plans to enroll an estimated 680 participants and plans to start in November 2026. It is a multicenter, randomized, open-label Phase III trial comparing once-weekly SHR-3167 with once-daily insulin degludec over up to 33 weeks.